Latest Conference Articles

The rate of severe radiation dermatitis was reduced with the use of Mepital Film in patients with breast cancer undergoing mastectomy.

A presentation at the 2022 ESMO Congress found that xevinapant plus chemoradiotherapy decreased the risk of death by twice that of placebo for patients with unresectable, locally advanced head and neck squamous cell carcinoma.

Linda Laskowski-Jones, MS, APRN, ACNS-BC, CEN, NEA-BC, FAAN, discusses how oncology nurse leaders can help improve working environments for their staff.

At the 2022 ASCO Quality Care Symposium, researchers discussed how Medicaid expansion was tied to earlier diagnoses, more accessible palliative care, and decreased mortality rates for patients with cancer.

Tivozanib, an oral VEGF inhibitor, improved overall survival in patients with relapsed or refractory, advanced renal cell carcinoma.

At the 2022 ASCO Quality Care Symposium, an adverse event analysis showed that abemaciclib has a manageable safety profile and that dose reductions may be a key aspect of appropriate symptom management.

Neratinib was associated with a clinical benefit rate of 45.5% among patients with metastatic or recurrent HER2-mutated cervical cancer.

In this episode of "The Vitals," Milagros Elia, MA, APRN, ANP-BC, highlights how oncology nurses play a role in ongoing conversations regarding the intersection of climate change and public health.

Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.

Milagros Elia, MA, APRN, ANP-BC, discusses ways that nurses can advocate for their patients and help them manage health-related symptoms in the context of changing local environments.

For patients receiving an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer, the addition of abemaciclib doubled median progression-free survival vs placebo.

Sotorasib doubled the progression-free survival rate in patients with KRAS G12C–mutated non–small cell lung cancer.

Julie Malo, CCRP, a research nurse with the University of Montreal, discusses a nurse-directed initiative examining how the gut microbiome affects immune checkpoint blockade responses in patients with non–small cell lung cancer.

Patients with hepatocellular carcinoma achieved a median overall survival of 15.9 months with tislelizumab and 14.1 months with sorafenib.

In a real-world analysis of patients with hepatocellular carcinoma, the median overall survival with lenvatinib was 9.7 months in the low-dose group and 7.6 months in the recommended-dose group.

In a presentation at the 2022 Oncology Nursing Society Bridge, Stephany L. Rodriguez, RN, MS, NP, discussed the later effects associated with hematopoietic stem cell transplant and how to manage them.

Kristin Daly, MSN, ANP-BC, AOCNP, discusses the clinical significance of tumor variants and how they are changing the direction of cancer care.

At a median follow-up of 33.0 months, the median progression-free survival with tumor-infiltrating lymphocyte therapy was 7.2 months vs 3.1 months with ipilimumab.

Results of retrospective analysis of previously treated patients with metastatic renal cell carcinoma who received nivolumab in the second- and third-line showed that health-related quality of life was maintained in the real-world setting

Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The rate of event-free survival associated with pembrolizumab was significantly higher among patients with high-risk melanoma about to undergo surgery than among those who received immunotherapy following surgery.

After 10 months of follow-up, the confirmed objective response rate among patients with metastatic gastric cancer or gastroesophageal junction adenocarcinoma who received trastuzumab deruxtecan was 41.8%.

Karen Hande, PhD(c), DNP, ANP-BC, CNE, FAANP, ANEF, explains the difference between some of the popular cannabinoid products that patients with cancer may be taking.

A multicentre, retrospective study showed that treatment-related adverse effects associated with atezolizumab plus bevacizumab were prognostic of improvements in survival outcomes in patients with hepatocellular carcinoma.

Patients with relapsed or refractory metastatic colorectal cancer who received dose-optimized regorafenib achieved superior survival outcomes than those who received best supportive care, fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil.

Neoadjuvant immunotherapy starkly outperformed neoadjuvant chemotherapy in eliciting major pathological responses among patients with mismatch repair–deficient colon cancer, according to investigators.

The relapse-free survival rate was 22.3% among patients with resectable stage IIIB to IV M1a melanoma who received neoadjuvant talimogene laherparepvec versus 15.2% among those who received surgery alone.

Patients with triple-negative breast cancer who received pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores compared with patients who received placebo.